(MREO) – Mereo’s Alvelestat shows encouraging data on biomarkers in bronchiolitis obliterans syndrome
- Mereo BioPharma Group plc (NASDAQ: MREO) announced data from an interim analysis of a researcher-initiated study of alvelestat in patients with bronchiolitis obliterans syndrome (BOS) after hematopoietic stem cell transplantation (HCT) .
- The phase 1b / 2 study, conducted under a clinical trial agreement between Mereo and the National Cancer Institute, plans to enroll a total of 30 patients.
- The main endpoints of the study are to define the safety and the optimal biological dose based on the inhibition of neutrophil elastase measured using biomarkers at eight weeks and clinical efficacy at six months.
- Interim data from the first seven patients were presented at the American Society of Hematology’s 2020 annual meeting in December 2020.
- Six patients had stable disease, while one patient had progression to pneumonia.
- Subsequent analysis demonstrated that the six patients with elevated desmosine levels at baseline (pre-treatment) showed a reduction in the dose escalation period of desmosine within the subject by week eight.
- A median reduction of 13.9% from baseline was observed at week eight, with a maximum reduction of 52%.
- Additional biomarker analyzes of the first seven patients are ongoing and should be presented at ASH 2021.
- BOS is an inflammatory disease that affects the bronchioles, the smallest airways in the lungs.
- Price action: MREO shares are up 2.1% to $ 3.53 in the last check market session on Wednesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.